Is Orexo AB - ADR (ORXOY) Stock a Good Investment?
Learn more about Orexo AB - ADR's (ORXOY) stock grades for Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Commentary & Analysis
Financial Summary
| Share Statistics | ORXOY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $47.9 | $609.5 | 15% |
|
| Shares Out (Mil) | 3.6 | 43.4 | 11% |
|
| Institutional Ownership | 32.0% | 83.9% | 13% |
|
| Float (Mil) | 21.3 | 45.7 | 30% |
|
| Beta | 0.89 | 0.73 | 53% |
|
| Avg Daily Volume (000s) | 1 | 309 | 4% |
|
| Price Change (52-week) |
(80.1%) | 64.9% | 7% |
|
| Growth | ORXOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (49.0%) | 6.7% | 0% |
|
| Net Income (5yr) | 54.3% | (1.6%) | 95% |
|
| EPS (5yr) | 54.1% | 15.1% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 35.2% | (15.0%) | 89% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ORXOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $317 | 3% |
|
| Net Income (TTM) (Mil) | $48 | ($11) | 54% |
|
| EPS (TTM) | $1.366 | ($0.700) | 65% |
|
| Operating Cash Flow (TTM) (Mil) | $67 | ($7) | 48% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $28 | $525 | 13% |
|
| Valuation | ORXOY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.61 | na |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ORXOY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 38.0% | 68.8% | 47% |
|
| Net Margin | na | 0.8% | na |
|
| ROA | 87.0% | (22.7%) | 100% |
|
| ROE | na | (22.8%) | na |
|
| Liabilities to Assets | 47.3% | 33.1% | 39% |
|
| F-Score | na | 3 | na |
|
Orexo AB (publ) did not pass any screens on 9/11/2026.
